Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: J Immunol. 2018 Aug 13;201(7):2094–2106. doi: 10.4049/jimmunol.1800578

Figure 2. IL-2/JES6–1 immunocytokine fusion fails to recapitulate TReg-promoting activity of the mixed antibody-cytokine complex.

Figure 2.

(a) Schematic of the IL-2/JES6–1 single-chain immunocytokine (IC) fusion with the C-terminus of the cytokine tethered to the N-terminus of the antibody light chain via a (Gly4Ser)2 flexible linker. (b) Equilibrium surface plasmon resonance titrations of soluble IL-2 (gray) or JES6–1 IC (blue) binding to immobilized IL-2Rα. Fitted equilibrium dissociation constants (KD) are indicated. (c) STAT5 phosphorylation response (mean ± S.D.) of IL-2Rα+ (top) or IL-2Rα− (bottom) YT-1 human NK cells stimulated with IL-2, IL-2/JES6–1 complex, or JES6–1 IC. (d) Ratio of TReg to CD8+ effector T cell abundance in spleens harvested from non-obese diabetic (NOD) mice (n=4 per cohort) treated with PBS, IL-2, IL-2/JES6–1 complex, or JES6–1 IC for four consecutive days. Data represents mean ± s.d. Statistical significance was determined by two-tailed unpaired Student’s t-test. The experiment was performed three times with similar results.